Korro Bio (KRRO) Svp, Finance Oliver Dolan Sells $37K of Stock

Oliver Dolan Trims Stake in Korro Bio

Oliver Dolan, Senior Vice President of Finance at Korro Bio, Inc. (NasdaqCM: KRRO), sold 3,383 shares of the company's stock on June 16, 2026. The shares were disposed of at a price of $10.83, bringing the total value of the transaction to $36,637.89. This sale was not executed under a pre-arranged Rule 10b5-1 trading plan and added to a busy sequence of insider transactions at the Cambridge-based biotechnology firm during the month of June.

Insider Buying and Selling at Korro Bio, Inc.

Dolan's transaction was part of a coordinated cluster of insider sales that took place on June 16, 2026. On that exact date, Chief Operating Officer Todd Chappell sold 3,168 shares at $10.83 per share for a total of $34,309.44, while Chief Scientific Officer Loic Vincent parted with 3,418 shares at the same price for a total of $37,016.94. These mid-June sales preceded a larger string of planned dispositions by insider Formela Jean Francois later in the month, continuing a pattern of executive share reductions that caught market attention.

Korro Bio Stock Context and Valuation

Shares of Korro Bio traded hands around $11.05 recently, hovering close to its 200-day moving average of $11.58. The stock has experienced a wide 52-week trading range, moving between a low of $5.20 and a high of $55.89, with a market capitalization of roughly $146.96 million. Because the company is still in its clinical development phase, it posts a negative earnings per share of $9.88 and does not carry a traditional positive price-to-earnings ratio.

Analysts Set New Price Targets

Wall Street firms following the biotech company maintain a largely positive outlook despite the recent executive sales activity. Analysts have established a consensus mean price target of $20.20 for the stock, with targets stretching from a low of $10.00 up to $30.00 across ten analyst opinions. On October 6, 2026, HC Wainwright & Co. reiterated its buy rating on KRRO with a price target of $15.00, following an earlier reiteration at the same target on August 20, 2026.

Inside the Biotechnology Business

Korro Bio focuses on discovering and developing genetic medicines by editing RNA for the treatment of rare and prevalent diseases. Headquartered in Cambridge, Massachusetts, the firm utilizes its proprietary platform to create differentiated product candidates, including its lead candidate KRRO-121 for hyperammonemia, alongside programs targeting neurological conditions and a partnership with Novo Nordisk A/S.

What to Watch Next for KRRO

Investors tracking Korro Bio will look toward the company's next scheduled financial results report, which is expected around November 12, 2026. Further SEC filings will also clarify whether executives continue to adjust their holdings through the remainder of the year.